RUDN biochemists found out how ROS affect cisplatin resistance in ovarian cancer cells

September 13, 2018

Long-term use of anti-cancer drugs treatment may lead to the development of multiple drug resistance reducing the efficiency of chemotherapy. Scientists are aware of several mechanisms for drug resistance development in tumor cells. They are to a great extent associated with the activation of proteins that get medicinal drugs out of cells, as well as with changes in the genes controlling cell survival and programmed cell death (apoptosis). One of the least studied mechanisms of drug resistance development is connected with the influence of reactive oxygen species (ROS) that are formed during cell life and can destroy organic molecules.

RUDN biochemists studied the mechanism of drug resistance development in ovarian cancer cells under treatment with cisplatin. The researchers found out that the process was connected with increased expression (production of proteins coded by DNA molecules) of genes of key antioxidant enzymes (i.e. destroying ROS): Mn-superoxide dismutase, catalase, glutathione peroxidase-1, hemoxygenase-1, as well as reduced expression of the enzyme NADPH-oxidase, which is responsible for ROS generation in the cell.

In the normal state there is a balance between the formation and destruction of ROS. Any changes in this balance may cause damage in the internal structure of the cells leading to number of diseases including cancer. On the other hand, high concentrations of ROS may also lead to the death of cancer cells. This effect is used in cancer therapy, and cisplatin may operate on a similar principle.

In their work the scientists used the real time RT-PCR method and western blotting to evaluate gene expression. The discovered redox-dependent mechanism of drug resistance development shows how well tumor cells can adapt to negative environmental conditions. The mechanism helps healthy cells survive, but in case of malignant tumors hinders their treatment.

"We found that under treatment of the ovarian cancer cells with cisplatin a new mechanism is triggered, changing the balance between generation and elimination of ROS; it is called as the adaptive antioxidant response. The studied mechanism of drug resistance development would help create new combined methods for ovarian cancer treatment," said Elena Kalinina, the author of the study, doctor of biological science, and professor of RUDN Institute of Medicine.
-end-


RUDN University

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.